株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腫瘍浸潤性リンパ球 (TIL):癌免疫療法の新たなフロンティア

Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy

発行 BCC Research 商品コード 882253
出版日 ページ情報 英文 21 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
腫瘍浸潤性リンパ球 (TIL):癌免疫療法の新たなフロンティア Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy
出版日: 2019年07月03日 ページ情報: 英文 21 Pages
概要

当レポートでは、癌免疫療法の新たなフロンティアとしての腫瘍浸潤性リンパ球 (TIL) のR&D動向を調査し、腫瘍浸潤性リンパ球 (TIL) の概要、転移性黒色腫・その他の腫瘍におけるTIL治療薬の開発動向、主要企業・研究センターによる臨床開発動向などをまとめています。

第1章 TILを用いた細胞治療の出現

第2章 転移性黒色腫におけるTIL治療薬の開発

  • TILの発生
  • リンパ球枯渇の重要性
  • インターロイキン2の役割
  • 主流の治療オプションとしてのTILのフィージビリティ

第3章 他の腫瘍タイプにおけるTIL治療薬の開発

  • 子宮頸癌
  • 卵巣癌
  • 腎臓癌
  • 消化器癌
  • 頭頸部癌

第4章 TIL治療薬の臨床開発

  • Lifileucel (LN-144):Iovance Biotherapeutics
  • LN-145:Iovance Biotherapeutics
  • TILT-123:TILT Biotherapeutics
  • Optera Therapeutics Corp.
  • その他のTIL研究センター
  • 将来の展望

第5章 文献

図表

List of Tables

  • Table 1: TILs and Tumor Specific Antigens
  • Table 2: Adoptive T-Cell Therapy (ATC) Cellular Therapies
  • Table 3: Clinical Trials Studying TIL Therapies

List of Figures

  • Figure 1: Generation of Tumor Infiltrating Lymphocytes
  • Figure 2: IL-2 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types
  • Figure 3: TILT Biotherapeutics Development Pipeline
目次
Product Code: BIO129A

Report Highlights:

This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.

This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.

Report Includes:

  • An overview of Tumor Infiltrating Lymphocytes (TILs) for the treatment of metastatic cancer
  • Discussion of the development of TIL as a treatment option for melanoma and the possibilities to expand this therapy to other types of cancer
  • Exploration of adoptive T-cell therapy (ATCT) using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma, and the curative potential of ATCT in a variety of other solid tumors
  • Comparison between two main technologies of tumor immunotherapy, chimeric antibody receptor engineered T Cell (CAR-T) and genetically modified T cell receptors (TCR)
  • Information on the role of TILs as a strong prognostic biomarker for triple-negative breast cancer (TNBC) and their potential ramifications

Table of Contents

Chapter 1: The Emergence of Cell Therapy Using TILs

  • Introduction
  • Analyst's Credentials
  • Related Reports

Chapter 2: Development of TIL Therapies in Metastic Melanoma

  • TIL Generation Explained
  • Importance of Lymphodepletion
  • Role of Interleukin-2
  • Feasibility of TIL as a Mainstream Treatment Option

Chapter 3: Development of TIL Therapies in Other Tumour Types

  • Cervical Cancer
  • Ovarian Cancer
  • Kidney Cancer
  • Gastrointestinal Cancer
  • Head and Neck Cancers

Chapter 4: Clinical Development of TIL Therapies

  • Lifileucel (LN-144), Iovance Biotherapeutics
  • LN-145, Iovance Biotherapeutics
  • TILT-123, TILT Biotherapeutics
  • Optera Therapeutics Corp.
  • Other Centers Conducting TIL Research
  • Future Perspectives for TIL

Chapter 5: References

Back to Top